This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Stocks Insiders Love Right Now

Synageva BioPharma

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

In the biotechnology and drugs complex, insiders are loading up on Synageva BioPharma (GEVA - Get Report), which is focused on the discovery, development and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical needs. Insiders are buying this stock into some big-time strength here, since shares are up over 80% so far in 2012.

Synageva BioPharma has a market cap of $1.04 billion and an enterprise value of $903 million. This stock trades at a premium valuation, with a price-to-sales of 235.20 and a price-to-book of 6.85. Its estimated growth rate for this year is 78.6%, and for next year it's pegged at -51.10%. This is a cash-rich company, since the total cash position on its balance sheet is $138.92 million, and its total debt is zero.

>>5 Biotech Stocks Under $10 Set to Soar

A director and beneficial owner just bought 886,000 shares, or about $36.5 million worth of stock, at $41.20 per share. Another director also just bought 73,000 shares, or about $3 million worth of stock, at $41.20 per share.

From a technical perspective, GEVA is currently trading above both its 50-day and 200-day moving averages, which is bullish. This stock triggered a major breakout trade back in late June once it started to move above some past overhead resistance at $40.38 with massive upside volume. Following that trigger, shares of GEVA pulled back briefly to around $40 a share, and then took off to hit its recent 52-week high of $49.93 a share. That move has started to push GEVA into overbought territory, since its current relative strength index reading is 80.42.

If you're in the bull camp on GEVA, then I would wait for this stock to pullback significantly since it's extended by almost ten points above its 50-day moving average of $39.28 a share, and it's almost twenty points above its 200-day moving average of $30.36 a share. Look for a buying opportunity in GEVA once it pulls back closer to its 50-day moving average of $39.28 a share, at let's say $42 to $40 a share if we get it.

3 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
GEVA $104.73 0.00%
DECK $72.05 0.00%
IMAX $36.65 0.00%
HSON $2.96 0.00%
PAY $36.17 0.00%

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs